Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.
Oncology Nursing News Staff
Advertisement
Articles by Oncology Nursing News Staff
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
2
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
3
Improving Patient Adherence Through Integrative Oncology Care
4
Advanced Practice Providers Leading Quality Improvement in Oncology Care
5